Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;135(5):1368-1376.
doi: 10.1038/jid.2015.11. Epub 2015 Jan 23.

The role of eIF4E in response and acquired resistance to vemurafenib in melanoma

Yao Zhan  1 , Michael S Dahabieh  1 , Arjuna Rajakumar  1 , Monica C Dobocan  2 , Marie-Noël M'Boutchou  2 , Christophe Goncalves  2 , Shiru L Lucy  1 , Filippa Pettersson  2 , Ivan Topisirovic  3 , Léon van Kempen  3 , Sonia V Del Rincón  2 , Wilson H Miller Jr  4
Affiliations
Free article

The role of eIF4E in response and acquired resistance to vemurafenib in melanoma

Yao Zhan et al. J Invest Dermatol. 2015 May.
Free article

Abstract

In eukaryotic cells, the rate-limiting component for cap-dependent mRNA translation is the translation initiation factor eIF4E. eIF4E is overexpressed in a variety of human malignancies, but whether it has a role in melanoma remains obscure. We hypothesized that eIF4E promotes melanoma cell proliferation and facilitates the development of acquired resistance to the BRAF inhibitor vemurafenib. We show that eIF4E is overexpressed in a panel of melanoma cell lines, compared with immortalized melanocytes. Knockdown of eIF4E significantly repressed the proliferation of a subset of melanoma cell lines. Moreover, in BRAF(V600E) melanoma cell lines, vemurafenib inhibits 4E-BP1 phosphorylation, thus promoting its binding to eIF4E. Cap-binding and polysome profiling analysis confirmed that vemurafenib stabilizes the eIF4E-4E-BP1 association and blocks mRNA translation, respectively. Conversely, in cells with acquired resistance to vemurafenib, there is an increased dependence on eIF4E for survival; 4E-BP1 is highly phosphorylated and thus eIF4E-4E-BP1 associations are impeded. Moreover, increasing eIF4E activity by silencing 4E-BP1/2 renders vemurafenib-responsive cells more resistant to BRAF inhibition. In conclusion, these data suggest that therapeutically targeting eIF4E may be a viable means of inhibiting melanoma cell proliferation and overcoming vemurafenib resistance.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nature. 2011 Nov 23;480(7377):387-90 - PubMed
    1. J Dermatol Sci. 2013 Dec;72 (3):284-9 - PubMed
    1. PLoS One. 2011;6(12 ):e28973 - PubMed
    1. Future Med Chem. 2013 Dec;5(18):2185-97 - PubMed
    1. Future Oncol. 2012 May;8(5):499-507 - PubMed

Publication types

MeSH terms

LinkOut - more resources